e-learning
resources
Munich 2014
Monday, 08.09.2014
Pulmonary hypertension: novel targets and drugs
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist
J. Gatfield, K. Menyhart, O. Nayler (Allschwil, Switzerland)
Source:
International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Session:
Pulmonary hypertension: novel targets and drugs
Session type:
Thematic Poster Session
Number:
2353
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Gatfield, K. Menyhart, O. Nayler (Allschwil, Switzerland). Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist. Eur Respir J 2014; 44: Suppl. 58, 2353
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Michael Klein (München, Germany) - 07.09.2014 23:57
hello, excellent poster! is it possible to receive the poster?thank you, best wishes,michael klein
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Neuron-derived orphan receptor 1 mediated human pulmonary arterial smooth muscle cells proliferation via cyclin D1
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
PKCalpha deficiency in mice is associated with pulmonary vascular hyperresponsiveness to thromboxane A
2
via increased TXA
2
receptor expression
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Nuclear factor-kappa B inhibition exerts anti-remodelling effects in pulmonary arterial smooth muscle cells
Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Year: 2014
Obligatory role of MEK/ERK/RSK90 in the mitogenic responses of human pulmonary artery smooth muscle cells
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Anti-fibrotic effects of pirfenidone on pulmonary arterial vascular smooth muscle cells
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Treprostinil prodrugs for pulmonary arterial hypertension evaluated in cAMP profiling studies in live CHO-K1 cells
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Acid sphingomyelinase, a novel pathway for pulmonary vasoconstriction. Activation by apoptotic T cell microparticles and Fas ligand
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Role of endothelin B receptor in Th2-induced pulmonary vascular hyperresponsiveness
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013
Nuclear IL-33 arguments ST2 receptor expression in pulmonary arterial endothelial cells: Implication in the pathogenesis and progression of pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Antiproliferative effects of drugs affecting different signalling pathways on rat and human pulmonary artery smooth muscle cells
Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH
Year: 2015
MicroRNA-155 controls pulmonary artery fibroblast cell signalling and proliferation in a knockout mouse model: A role in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Activation of AMPK inhibits pulmonary arterial remodeling
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Prevention of monocrotaline-induced pulmonary vascular and myocardial remodeling by the selective neutrophil elastase inhibitor BAY 85-8501
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Anti-remodeling potencies of the soluble guanylate cyclase activator BAY 41-2272 in human lung fibroblasts
Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Year: 2014
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011
Insulin-like growth factor-1 contributes to the pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
M2 macrophages derived from patients with idiopathic pulmonary arterial hypertension are susceptible for apelin-mediated suppression of pro-inflammatory cytokines
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Endothelial-derived MIF contributes to pulmonary endothelial cell proliferation in human pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept